Welcome to LookChem.com Sign In|Join Free
  • or
1(2H)-Pyridinecarboxylic acid, 4-(4-bromophenyl)-3,6-dihydro-, 1,1-dimethylethyl ester, commonly known as 4-bromo-3,6-dihydro-4-(4-methylphenyl)-2-pyridinecarboxylic acid tert-butyl ester, is a complex chemical compound belonging to the pyridinecarboxylic acid family. It is a tert-butyl ester derivative of the 4-(4-bromophenyl)-3,6-dihydro-1(2H)-pyridinecarboxylic acid, characterized by its structural properties and reactivity.

273727-44-9

Post Buying Request

273727-44-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

273727-44-9 Usage

Uses

Used in Pharmaceutical Industry:
1(2H)-Pyridinecarboxylic acid, 4-(4-bromophenyl)-3,6-dihydro-, 1,1-dimethylethyl ester is used as an intermediate in the production of various pharmaceuticals. Its unique structural properties and reactivity make it a valuable component in the synthesis of a wide range of medicinal compounds.
Used in Agrochemical Industry:
In the agrochemical industry, 1(2H)-Pyridinecarboxylic acid, 4-(4-bromophenyl)-3,6-dihydro-, 1,1-dimethylethyl ester is utilized as a key intermediate in the development of various agrochemicals. Its structural versatility allows for the creation of compounds with specific applications in agriculture, such as pesticides and herbicides.
Used in Organic Compounds Synthesis:
1(2H)-Pyridinecarboxylic acid, 4-(4-bromophenyl)-3,6-dihydro-, 1,1-dimethylethyl ester is also employed in the synthesis of other organic compounds due to its reactivity and structural characteristics. This makes it a versatile building block for creating a variety of molecules with different applications in various industries.

Check Digit Verification of cas no

The CAS Registry Mumber 273727-44-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,7,3,7,2 and 7 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 273727-44:
(8*2)+(7*7)+(6*3)+(5*7)+(4*2)+(3*7)+(2*4)+(1*4)=159
159 % 10 = 9
So 273727-44-9 is a valid CAS Registry Number.

273727-44-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-(4-bromophenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester

1.2 Other means of identification

Product number -
Other names tert-butyl 4-(4-bromo-phenyl)-3,6-dihydropyridine-1(2H)-carboxylate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:273727-44-9 SDS

273727-44-9Relevant academic research and scientific papers

BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER

-

Page/Page column 102; 103, (2021/05/07)

The invention provides bifunctional compounds of formula (I) or a pharmaceutically acceptable salt thereof. Formula (I). The compounds cause the degradation of SMARCA2 via the targeted ubiquination of SMARCA2 protein and subsequent proteasomal degradation and are thus useful for the treatment of cancer. The targeting ligand is of formula (TL).

SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS

-

Page/Page column 158-159, (2021/05/07)

Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, and R5 are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Exploration of Alternative Scaffolds for P2Y14Receptor Antagonists Containing a Biaryl Core

Jung, Young-Hwan,Yu, Jinha,Wen, Zhiwei,Salmaso, Veronica,Karcz, Tadeusz P.,Phung, Ngan B.,Chen, Zhoumou,Duca, Sierra,Bennett, John M.,Dudas, Steven,Salvemini, Daniela,Gao, Zhan-Guo,Cook, Donald N.,Jacobson, Kenneth A.

supporting information, p. 9563 - 9589 (2020/09/02)

Various heteroaryl and bicyclo-aliphatic analogues of zwitterionic biaryl P2Y14 receptor (P2Y14R) antagonists were synthesized, and affinity was measured in P2Y14R-expressing Chinese hamster ovary cells by flow cytometry. Given this series' low water solubility, various polyethylene glycol derivatives of the distally binding piperidin-4-yl moiety of moderate affinity were synthesized. Rotation of previously identified 1,2,3-triazole attached to the central m-benzoic acid core (25) provided moderate affinity but not indole and benzimidazole substitution of the aryl-triazole. The corresponding P2Y14R region is predicted by homology modeling as a deep, sterically limited hydrophobic pocket, with the outward pointing piperidine moiety being the most flexible. Bicyclic-substituted piperidine ring derivatives of naphthalene antagonist 1, e.g., quinuclidine 17 (MRS4608, IC50 ≈ 20 nM at hP2Y14R/mP2Y14R), or of triazole 2, preserved affinity. Potent antagonists 1, 7a, 17, and 23 (10 mg/kg) protected in an ovalbumin/Aspergillus mouse asthma model, and PEG conjugate 12 reduced chronic pain. Thus, we expanded P2Y14R antagonist structure-activity relationship, introducing diverse physical-chemical properties.

Azabenzimidazole derivative having AMPK-activating activity

-

Page/Page column 71, (2017/03/08)

Disclosed is a compound which is useful as an AMPK activator. A compound represented by formula: or a pharmaceutically acceptable salt thereof, wherein R4 is hydrogen, or substituted or unsubstituted alkyl, R1, R2 and R3 are each independently hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl or the like, with the proviso that R1, R2 and R3 are not simultaneously hydrogen, X is a single bond, —S—, —O—, —NR5—, —C(═O)— or the like, R5 is hydrogen, or substituted or unsubstituted alkyl, Y is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl or the like.

PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS

-

Paragraph 0638-0639, (2017/01/31)

The present invention provides a heterocyclic compound having a TLR7, TLR9, TLR7/8, TLR7/9 or TLR7/8/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases, inflammatory diseases and the like, in particular, systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

HETEROCYCLIC COMPOUNDS

-

Paragraph 0253; 0254, (2017/03/21)

The present invention provides a heterocyclic compound a TLR7 and/or TLR9 and/or TLR-7/8/9 and/or TLR-7/8 and/or TLR-7/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases and/or inflammatory diseases and the like, in particular, acute decompensated heart failure, non-alcoholic steatohepatitis (NASH), IgA nephropathy, Duchenne muscular dystrophy (DMD), systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease, asthma, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, B-cell malignancies, transplant rejection and graft-versus-host disease, hepatocellular carcinoma (HCC) and the like. The present invention is a compound represented by the formula (1) : wherein each symbol is as described in the specification, or a salt thereof.

METALLO-BETA-LACTAMASE INHIBITORS

-

, (2016/12/01)

The present invention relates to compounds of formula (I) that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.

METALLO-BETA-LACTAMASE INHIBITORS

-

, (2017/04/04)

The present invention relates to compounds of formula I that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.

METALLO-BETA-LACTAMASE INHIBITORS

-

, (2015/08/06)

The present invention relates to compounds of formula (I) that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.

PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS

-

Paragraph 0214, (2016/12/16)

The present invention provides a heterocyclic compound having a TLR7, TLR9, TLR7/8, TLR7/9 or TLR7/8/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases, inflammatory diseases and the like, in particular, systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 273727-44-9